

Henning Wege

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5231496/publications.pdf>

Version: 2024-02-01

28
papers

1,627
citations

516710

16
h-index

526287

27
g-index

28
all docs

28
docs citations

28
times ranked

2320
citing authors

#	ARTICLE	IF	CITATIONS
1	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	27.8	649
2	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. <i>BMC Cancer</i> , 2015, 15, 564.	2.6	182
3	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	3.7	132
4	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	7.3	114
5	Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. <i>Hepatology</i> , 2020, 72, 88-102.	7.3	76
6	Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling. <i>Journal of Biological Chemistry</i> , 2016, 291, 16186-16196.	3.4	70
7	Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection. <i>Oncotarget</i> , 2017, 8, 89978-89987.	1.8	58
8	Inflammation-Induced Expression and Secretion of MicroRNA 122 Leads to Reduced Blood Levels of Kidney-Derived Erythropoietin and Anemia. <i>Gastroenterology</i> , 2016, 151, 999-1010.e3.	1.3	53
9	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	4.9	36
10	Treatment Lines in Hepatocellular Carcinoma. <i>Visceral Medicine</i> , 2019, 35, 266-272.	1.3	31
11	Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. <i>Liver Cancer</i> , 2021, 10, 360-369.	7.7	25
12	High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection. <i>BMC Cancer</i> , 2017, 17, 60.	2.6	24
13	Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients. <i>Cancers</i> , 2021, 13, 2484.	3.7	23
14	Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas. <i>European Journal of Medical Genetics</i> , 2021, 64, 104313.	1.3	19
15	Telomerase Activation in Liver Regeneration and Hepatocarcinogenesis: Dr. Jekyll or Mr. Hyde?. <i>Current Stem Cell Research and Therapy</i> , 2007, 2, 31-38.	1.3	17
16	Transduction of Fetal Mice With a Feline Lentiviral Vector Induces Liver Tumors Which Exhibit an E2F Activation Signature. <i>Molecular Therapy</i> , 2014, 22, 59-68.	8.2	17
17	Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease. <i>United European Gastroenterology Journal</i> , 2018, 6, 238-246.	3.8	17
18	Regeneration in pig livers by compensatory hyperplasia induces high levels of telomerase activity. <i>Comparative Hepatology</i> , 2007, 6, 6.	0.9	16

#	ARTICLE	IF	CITATIONS
19	Forced Activation of β -Catenin Signaling Supports the Transformation of <i>hTERT</i> -Immortalized Human Fetal Hepatocytes. <i>Molecular Cancer Research</i> , 2011, 9, 1222-1231.	3.4	16
20	Specific genomic and transcriptomic aberrations in tumors induced by partial hepatectomy of a chronically inflamed murine liver. <i>Oncotarget</i> , 2014, 5, 10318-10331.	1.8	15
21	Fast and facile analysis of glycosylation and phosphorylation of fibrinogen from human plasma—correlation with liver cancer and liver cirrhosis. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 7965-7977.	3.7	12
22	First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma—An Update on Patient Selection and Response Evaluation. <i>Diagnostics</i> , 2016, 6, 44.	2.6	11
23	Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort. <i>Visceral Medicine</i> , 2021, 37, 87-93.	1.3	6
24	Constitutive gp130 activation rapidly accelerates the transformation of human hepatocytes via an impaired oxidative stress response. <i>Oncotarget</i> , 2016, 7, 55639-55648.	1.8	3
25	36—Tumor-immune signatures associated with response or resistance to tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC). , 2021, 9, A387-A387.		2
26	Perforation of the ascending colon during implantation of an indwelling peritoneal catheter: a case report. <i>BMC Gastroenterology</i> , 2020, 20, 345.	2.0	1
27	Equal Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative Treatment. <i>Cancers</i> , 2022, 14, 768.	3.7	1
28	Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic. <i>PLoS ONE</i> , 2021, 16, e0258450.	2.5	1